scopic imaging study of AD at this laboratory (8), abnormalities were noted in metabolite ratios of NAA and choline-and creatine-containing compounds in white and gray matter of the centrum semiovale. In the white matter of patients with AD, the ratios of NAA to choline and NAA to creatine were reduced relative to those in control subjects in the absence of variations in the levels of choline or creatine; these results imply that decreased NAA was primarily responsible for these changes.
Decreased levels of NAA in white matter suggest diffuse axonal loss or damage. In the mesial gray matter of patients with AD, the NAA-to-choline ratio was lower, and the choline-to-creatine ratio was higher compared with those in control subjects, which implies that these changes could be due to decreased NAA andlor increased choline. Decreased NAA in gray matter suggests neuronal loss, whereas increased choline may be a result of membrane breakdown products.
In the second study at this laboratory (9), in which similar H-1 MR spectroscopic imaging methods were used, we extended the observation of metabolic abnormalities in the centrum semiovale to a larger population of patients with AD and control subjects; in addition, this second study included a group of patients with subcortical ischemic vascular dementia. Although the findings from the AD and control groups were similar to the findings from the first study, different metabolite changes were noted in patients with subcortical ischemic vascular dementia, which supported the possibility that H-1 MR spectroscopic imaging may provide information to help differentiate AD from subcortical ischemic vascular dementia.
Finally, in the third study at this laboratory (lo), the extent to which these metabolic differences between patients and control subjects were independent of variations in the tissue composition of the MR spectroscopic imaging voxels (eg, enclosed amounts of gray matter, white matter, and high-signal-intensity white matter) was investigated. This analysis was made possible by using tissue segmentation information from MR imaging coregistered with the MR spectroscopic imaging data. Although the analysis revealed substantial variations in the tissue composition in the regions of interest, these changes did not contribute statistically significantly to the metabolite differences, which indicated that a reduced NAAto-choline ratio and an increased choline& creatine ratio in posterior mesial gray matter of patients with AD were not simply artifacts of these structural variations. Furthermore, MR spectroscopic imaging data combined with MR imaging segmentation data had a greater power to aid in correct classification of patients with AD and control subjects than either method had a!one.
There were limitations to these studies, however, including relatively small numbers of subjects and an early MR imaging technology with which relatively (compared with today's standards) thick sections (5 mm) and intersection gaps (0.5 mm) were used, which compromised the accuracy of tissue segmentation. Furthermore, acquisition of the MR spectroscopic imaging data was performed at a relatively long echo time of 272 msec (because of technical imperfections of an MR imager equipped with unshielded gradient coils), which reduced sensitivity and increased signal dependence on T2 effects. Finally, in these previous MR spectroscopic imaging studies, we reported metabolite ratios, which are difficult to interpret, rather than concentrations.
Therefore, the present study had several goals. First, we aimed to replicate previous findings that suggested the presence of reduced NAA levels and increased choline levels by using improved H-1 MR spectroscopic imaging techniques in a new and larger. population of patients with AD. In the present study, data were acquired with a shorter echo time (135 msec) to improve overall sensitivity and to reduce T2 dependency on the metabolite resonance intensities. In addition, the spectroscopic imaging data were expressed in terms of concentrations, to avoid use of metabolite ratios. Second, we sought to veri+ that these metabolic abnormalities are not simply artifacts of variations in the tissue composition of MR spectroscopic imaging voxels. This was accomplished by using MR imaging and semiautomated segmentation software to produce contiguous, 3-mm-thick sections aaoss the entire brain. Third, we sought to determine if NAA level changes correlate with clinical measures of the severity of dementia in AD patients. Finally, we sought to test whether MR spectroscopic imaging variables together with MR imaging segmentation variables provide better discrimination between patients with AD and control subjects than MR imaging segmentation variables alone. dard deviation) of 19.1 2 6.9 (ranged 8-30). The diagnosis of possible AD in four patients was based on the obselta. tion that, at the time of evaluation, three had thyroid problems and the fourth had suspected complications with lifelong alcohol abuse.
MATERIALS AND METHODS

Patients and Control Subjects
The patient data were compared with results in 22 subjects with normal cognition; these subjects were on average 8.7 years younger (mean age, 67.9 years -+ 7.3; age range, 52-85 years). For the purposes of analysis, the data from a subset of 17 AD patients and 17 control subjects of comparable age were first tested to determine the contribution of age to the MR spectroscopic imaging measures.
Initially, seven more patients and three more control subjects were enrolled in this study, but their data were not used for analysis because either the imaging acquisitions had to be terminated prernaturely because of the subject's request to be taken out of the magnet or data quality was severely degraded due to head movements during the acquisition.
All patients were recruited from the University of California at San Francisco Alzheimer Center; were examined by a neurologist; and underwent the standard battery of geriatric medical, neuropsychologic, psychiatric, and laboratory tests at the center. The 22 control subjects were recruited by posting flyers in community and retirement centers. They underwent an evaluation similar to that of the AD ' patients and were judged to have normal cognition. None of the patients or control subjects had evidence of stroke, cortical or subcortical infarctions, or other major abnormalities on MR images, which were read by a neuroradiologist (D.N.).
The study protocol was approved bv the committee on human research at the University of California at San Francisco, and all subjects or their legal guardians gave written informed consent before participation in the study. b. cover the entire brain from the inferior cerebellum to the vertex, 48-52 contiguous 3-mm-thick sections were acquired.
MR Imaging and MR Spectroscopic Imaging
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H-1 MR spectroscopic imaging data sets were acquired by using a spin-echo twodimensional MR spectroscopic imaging sequence (1,800/135 ) with preselection of a region of interest (point-resolved spectroscopic volume), which necessitated a total acquisition time of approximately 13 minutes. The point-resolved spectroscopic volume was angulated parallel to the double spin-echo imaging plane and was positioned immediately superior to the lateral ventricles as seen on the localizer image. Because of the different shape of the lateral ventricles in the participants, the point-resolved spectroscopic volume included a small fraction of the ventricles, in some cases. The anteroposterior (length) and right-left (width) dimensions of the point-resolved spectroscopic volume (mean length, 105.3 mm; mean width, 71.1 mm) were adjusted on axial MR images in every participant, according to the brain size. Section thickness was constant at 15 mm. m i c a 1 angulation and position of a point-resolved spectroscopic volume are depicted in Figure 1 . The MR spectroscopic imaging field of view was 210 x 210 mm and was sampled by using a reduced k-space sampling scheme over a circularly restricted region equivalent to a maximum of 24 x 24 phaseamding steps (13), which resulted in a nominal MR spectroscopic imaging spatial resolution of 0.8 x 0.8 mm.
The spectral sweep width was 1, OOO Hz.
MR Image Segmentation
Semiautomated, interactive computer segmentation of the MR images into specific tissue and anatomic compartments was performed by using software developed at our institution by one of the authors (G.F.). All brains were segmented on images into areas of ventricular CSF, sulcal CSF, cortical and subcortical gray matter, white matter, and hyperintense white matter.
Two trained operators (D.L.A., J.L.T.), both blinded to the participants' identity, processed the MR images. Editing of subcortical gray matter and hyperintense white matter regions was performed by one operator (I.L.T.). All values were normalized to the total number of pixels, expressed as a percentage of the intracranial volume. Reliability of image segmentation was evaluated by one of the authors (G.F.), who used a total of 20 segmentation images in 10 control subjects. The control subjects underwent imaging twice, and images 1 and 2 in each subject were segmented by a different operator. The coefficient of variation was 1.9% of the mean value for gray matter and 2.3% of that for white matter, which indicated that the accuracy of the segmentation measurement was far better than the intersubject variance, which typically was approximately 11% for gray matter and 8% for white matter. The interclass correlation coefficient was .961 for gray matter and .937 for white matter, which demonstrated that gray and white matter segmentation is practically independent of interoperator variations. Additional details about the segmentation procedure are available in reference 3.
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MR Spectroscopic Image Analysis
After acquisition, the MR spectroscopic imaging data were zero filled to a rectangular matrix of 32 x 32 X 1,024 points, were Fourier transformed, and were phaseand baseline-corrected by using software developed at our institution (14). Fourhertz Gaussian line broadening was used in the spectral direction, and mild Gaussian filtering was applied along the spatial directions to reduce Gibbs ringing effects, which resulted in an effective MR spectroscopic image resolution of approximately 1.1 x 1.1 mm. Spectra were extracted from nine regions of interest (voxels) within the point-resolved spectroscopic region by following guidelines described in detail by Meyerhoff et a1 (8) .
The size and typical location of the selected voxels are shown in Figure lb . Six lateral voxels were selected: two each in the frontal, middle, and posterior regions of the centrum semiovale (predominantly white matter). The remaining three voxels were selected from the midline of the brain: one each from a region of frontal, middle, and posterior mesial cortex (predominantly gray matter).
The MR resonances from NAA, creatine, and choline were curve fitted by using N M R~ software (New Research Methods, Syracuse, NY). Voxel selection and spectral fitting were performed by one trained operator (D.J.M.), who was blinded to the diagnosis in the participants. To estimate concentrations in milligrams per liter, the integral values of the metabolite resonances were referenced to values obtained from a head-sized phantom and included corrections for coil loading, receiver gain, and metabolite T1 and T2 by using previously reported (15) MR spectroscopic T1 and T2 values in healthy elderly subjects. It was assumed that the metabolite relaxation rates were the same for AD patients and control subjects and for gray and white matter.
To verify that metabolic changes were not an artifact of variations in the tissue composition of MR spectroscopic imaging voxels, tissue enclosed in each voxel was analyzed for amounts of gray matter, white matter, hyperintense white matter, and CSF by using software developed at our institution. This computation used the tissue-segmented MR images coregistered with MR spectroscopic imaging data and was performed with consideration of the MR spectroscopic imaging pointspread function, chemical shift displacements, and the signal sensitivity profile of the point-resolved spectroscopic volume, which was determined experimen- tally by using a head-sized phantom. The tissue content p, in each voxel was estimated with the following equation: p = gm + wm + wmsh, where gm, wm, and wmsh represent the enclosed amounts (ie, the number of pixels from the segmented MR images) of gray matter, white matter, and hyperintense white matter, respectively.
With the assumption that metabolite resonances are not detected in CSF, volume-corrected metabolite integrals were then computed by using metab = metab,/p, where metab and metab, are the corrected amount and uncorrected amount, respectively, of the metabolite. All MR spectroscopic metabolite values presented in this study are volume-corrected. Furthermore, the tissue composition in each voxel was characterized by computing tissue fraction factors for gray matter (XGM = gm/p), white matter (Xm = wm/p), and hyperintense white matter (XmsH = wmsh/p). For example, XGM is 1.0 for a voxel with pure gray matter and 0.0 for a voxel with white matter and hyperintense white matter but without gray matter. These factors were used as covariates for the statistical analysis to determine the extent to which the tissue composition contributed to metabolic differences.
Statistical Analysis
Because the AD patients in this study were on average statistically significantly older than the control subjects, metalx lite differences between the groups wer first tested in a subset of patients an subjects of comparable age to minim12 age effects. The Student t test was used t test for differences in the age distributic between groups.
Tests of metabolite differences betwet patients and control subjects were pe formed separately for the voxels from t1 mesial cortex and lateral centrum semi vale in frontal, middle, and poster11 brain, which resulted in a total of 5 comparisons. Metabolite differences b tween groups by tissue and region we tested with repeated-measures analysis 1 variance with the Bonferroni correctic for multiple comparisons. Analysis of vai ance was used to test whether metaboli changes were statistically significantly di ferent between male and female partic pants within each group. Finally, analys of covariance was used to test whethl the metabolite differences would remai statistically significant after adjustmei for differences in the tissue compositia of the MR spectroscopic imaging voxels Once the statistically significant m tabolite differences between patients an control subjects were identified in tf subset, the analysis was extended to ii clude data from the rest of the smc population, and between-group diffe ences were tested in a post-hoc mannc * Difference between patients and control subjects was statistically significant (P < .03).
+ Difference between patients and control subjects was statistically significant (P < .003).
tabolite changes and age was determined separately for patients and control sub-)ects by using an analysis of covariance. If age did not contribute significantly to metabolite changes, we continued the analysis of covariance to test whether metabolite differences between groups would remain significant after adjustment for variations in the tissue composition of the voxels. If age contributed fignificantly to the metabolite differences, the data were not further considered for analysis because it would not have been possible to distinguish changes related to AD from those associated with age.
Linear relationships between MR specmcopic imaging or MR imaging segmentation variables and MMSE scores in AD Were tested with the Pearson productmoment correlation. Linear discriminantfunction analysis was used to determine which MR imaging and MR spectroscopic imaging variables or combination of vari&s discriminated best between AD patients and control subjects. Results are expressed as means 2 the standard error of the mean, unless otherwise indicated. Table 1 lists the demographic data of the study population, together with the data of the selected subset of 17 AD patients and control subjects of comparable age. In the total study population, the mean age ( 2 1 standard deviation) of the AD patients was 76.6 years t 7.9, and that of the control subjects was 67.9 years 2 7.3; this age difference was statistically significant (P = .002). In the subset, the mean age of the AD patients was 73.0 years 2 8.0, and that of the control subjects was 69.5 years t 7.6; this difference was not significantly different (P = 2). In the total study population, the AD patients and control subjects were 51-87 years of age and had a similar number of years of education. Nineteen (68%) of the 28 AD patients and 10 (45%) of the 22 control subjects were women. The patients reported an average duration (51 standard deviation) of their symptoms related to AD of 4.3 years 2 2.3. The mean M M S E score ( 5 1 standard deviation) in AD patients was 19.1 5 6.9 (score range, 8-30), which was significantly lower (P < .001) than that in the control subjects (mean, 29.5 2 0.9).
RESULTS
Demographic Data
In comparison with the total group of AD patients in this study, the 17 AD patients in the subset were an average 3.6 years younger. The percentage of women in the AD subgroup further increased from 68% to 76% (13 of 17), while other demographic data did not change substantially. In comparison with the entire control group, the 17 control subjects in the subset were on average 1.6 years older and included a larger percentage of women (59% [lo of 17]), while other demographic data were virtually unchanged. Table 2 lists the mean concentrations of volume-corrected NAA, creatine, and choline from the mesial cortex and the centrum semiovale in frontal, middle, and posterior brain of the subset of AD patients and control subjects. The most prominent differences between AD patients and control subjects were lower levels in AD patients of NAA in the frontal mesial cortex and centrum semiovale and in the posterior mesial cortex. In the frontal brain in AD patients, NAA was reduced (relative to that in control subjects) by 14.0% in the mesial cortex (P < .03) and by 9.8% in the centrum semiovale (P < .003). In the posterior brain in AD patients, NAA was reduced (relative to that in control subjects) by 10.4% in the mesial cortex (P < .03), whereas in the centrum semiovale the difference was not statistically significant. In the middle brain of AD patients, NAA levels in both the cortex and the centrum semiovale were similar to those in control subjects.
MR Spectroscopic Imaging Results
The NAA levels were not significantly different between women and men in either the patient group or the control group. In contrast to the changes in NAA level, neither choline nor creatine levels were significantly different in any brain region in AD patients compared with the levels in control subjects.
MR imaging segmentation results from the age-matched cohort have been reported elsewhere (3). In that previous study, AD patients had a 10% decrease in cortical gray matter volume relative to the volume in control subjects (P < .OOOl)
and an 88Oh increase in hyperintense white matter volume (P < .005); white matter volume did not change significantly. One would expect that these structural changes are also reflected in the tissue composition of the selected MR spectroscopic imaging voxels, which could mimic metabolic differences if no adjustments are made. Table 3 lists the tissue composition of the MR spectroscopic imaging voxels corresponding to the regions listed in Table 2 . Overall, voxels in the frontal and posterior mesial cortex in AD patients enclosed significantly (P < .005) less gray matter (up to 13%) and, consequently, more whire matter than voxels from the corresponding region in control subjects, presumably because of larger gray matter loss in patients with AD. Furthermore, voxels from centrum semiovale white matter in AD patients contained more hyperintense white matter than those in controls, especially in frontal white matter, where the difference between the groups reached 120% (P <
.OOol).
To test whether the NAA differences were independent of differences in voxel tissue composition, analysis of covariance was performed by using the tissue fraction factors for gray matter (XGM) and hyperintense white matter (XwsH) of each voxel as covariates. In the frontal and posterior mesial cortex, NAA differences between the groups remained significant (P < .03) and variations of the tissue fraction factor for gray matter did not contribute significantly (P > .2) to the difference, which suggests that NAA reductions in these regions in AD patients are not simply an artifact of variations in the tissue composition of the voxels. Similarly, NAA differences between AD patients and control subjects in anterior centrum semiovale white matter remained significant (P < .003), and contributions from the tissue fraction factor for hyperintense white matter differences were not significant (P > .09), which suggests that increased hyperintense white matter in AD patients was not primarily responsible for the NAA difference.
Next, we extended the analysis of MR spectroscopic imaging data to the remaining 11 AD patients and five control subjects (but now restricted to the regions of frontal and posterior mesial cortical gray matter and frontal centrum semiovale white matter).
Because the AD patients were statistically significantly older than the control subjects, we first tested whether NAA Difference between patients and control subjects was statistically significant ( P < .005). + Difference between patients and control subjects was statistically significant ( P < .OS). t Difference between patients and control subjects was statistically significant ( P < .Owl).
changes in these regions were correlated with age. Over the age range studied, the NAA changes in AD patients were not statistically significantly (P > .1) related to age (r = -.17 for the frontal mesial cortex; r = -.11 for the posterior mesial cortex; r = -.W for the frontal centrum semiovale). Similar non-statistically significant (P > .l) results were obtained in control subjects (r = .15 for the frontal mesial cortex; r = -.lo for the posterior mesial cortex; r = -.13 for the frontal centrum semiovale). Furthermore, analysis of covariance results showed that age did not contribute significantly to NAA level differences between the groups at the different brain regions (P > .3 for all regions), which indicates that NAA levd variations cannot simply be explained iri terms of age effects. Dierence between patients and subjects was statistically significant ( P < .02).
more, these NAA level differences beween the groups remained significant after adjustment for variations in the tissue fraction factor for gray matter in these regions. In contrast to mesial cortex, NAA differences in the frontal centrum semiovale between AD patients and control subjects were not independent of differences in the hyperintense white matter composition of the MR spectroscopic imaging voxels. In this case, between-group differences in hyperintense white matter amounts enclosed in the MR spectroscopic imaging voxels contributed significantly (P < .01) to the NAA level differences, which suggests that reduced NAA level in frontal centrum semiovale white matter of AD patients is primarily an artifact of increased hyperintense white matter, This finding led us to investigate further the relationship between metabolite var!ations and tissue types. Figure 2a , 2b, and 2c display the variations of NAA, cre*ttine, and choline levels, respectively, in ID patients and control subjects as a function of the amount of gray matter enclosed in the selected voxels.
I n control subjects, NAA levels incre,ised modestly but significantly with incieased amount of gray matter (r = .35; P c .02), which indicates the presence of higner concentrations of NAA in gray ma:ter than in white matter. In contrast to the findings in control subjects, NAA levels in AD patients were not significaiitly correlated with the amount of gray rn'itter (r = .17; P > .l), which suggests t h t there are similar levels of NAA in white and gray matter, presumably becauce NAA reductions in cases of AD X\ ur primarily in gray matter and less so in white matter.
Changes in creatine levels were p s i -
Volume 207 * Number 1 tively correlated with the amount of gray matter in both AD patients (r = .59; P < .01) and control subjects (r = .63; P < .Ol), which indicates that there are higher levels of creatine in gray matter than in white matter. No significant correlation was found between choline and the amount of gray matter, which suggests that there are similar levels of choline in gray and white matter.
Finally, Figure 2d depicts the relationship of NAA level changes in AD patients and control subjects with the amount of hyperintense white matter enclosed in the MR spectroscopic-imaging voxels. In AD patients, NAA levels decreased significantly with increases in the amount of hyperintense white matter (r = .49; P < .Ol), which indicates that NAA level is reduced in hyperintense white matter compared with the level in normal white matter. This correlation seemed to be less prominent in control subjects; however, only a few voxels with large amounts of hyperintense white matter were available in the control subjects, and the determination of the correlation was therefore less accurate.
Neither creatine nor choline level showed a significant correlation with the amount of hyperintense white matter.
Overall, these results demonstrate the importance of accounting for variations in voxel tissue composition when one is analyzing H-1 MR spectroscopic imaging data.
We further tested whether reductions in NAA level in frontal or posterior mesial cortex of AD patients were related to the severity of dementia. Figure 3 depicts the changes in NAA level in the frontal and posterior mesial cortex of 26 AD patients as a function of dementia severity (MMSE score). (Two AD patients did not undergo the MMSE because they were not English speakers.) A weak but significant correlation was found between changes in NAA level in the posterior mesial cortex and severity of dementia (r = .42; P = .03), which suggests that the NAA level in this region may reflect some forms of cognitive impairment. N o significant correlation between NAA level and dementia severity was found for the frontal mesial cortex (r = .19, P > .3).
We also tested whether MR imaging segmentation variables were correlated with dementia severity. The percentage of sulcal CSF correlated significantly with severity of dementia in the AD group (r = -.46; P < .03), but correlation between other segmentation variables and dementia severity were not significant (percentage cortical gray matter, r = .38, P > .l; percentage of ventricular CSF, r = -.I& P > .1).
Finally, we tested the discrimination power of variables from MR imaging segmentation, from MR spectroscopic imaging, and from the combination of both to correctly classify AD patients and control subjects by using linear discriminantfunction analysis. The percentage of cortical gray matter was chosen as the MR imaging variable for the discrimination model because our previous MR imaging results (3) showed that total cortical gray matter loss provided the best performance in aid of the diagnosis of AD in comparison with other measures of morphologic changes (eg, ventricular and sulcal CSF enlargement). Mean NAA level in frontal and parietal gray matter was chosen as the MR spectroscopic imaging variable because NAA levels in these regions were significantly reduced in AD patients. The analysis was performed with results in 26 AD patients and 17 control subjects in whom complete sets of M R spectroscopic imaging and MR imaging data were acquired. Figure 4 depicts the distributions of the percentage of gray matter (Fig 4a) , N A A concentration (Fig 4b) , and the product of both variables (Fig 4c) in AD patients and control subjects. The 95% confidence intervals for each of the variables in the control group demonstrate that neither variable alone nor their combination is sufficient to help completely distinguish AD patients from control subjects. The percentage of cortical gray matter and NAA level can also be graphically compared in Figure 2a, Difference between patients and control subjects was statistically significant (P < .005).
+ Difference between patients and control subjects was statistically significant ( P < .0001).
* Difference between patients and control subjects was statistically significant (P < .OS). Our first major finding of reduced NAA levels in frontal and parietal gray and white matter confirms results of several previous studies from this (8-10) and other laboratories (15,16). Contrary to results from most previous studies, in which metabolite ratios were used, our results demonstrate that NAA concentrations are reduced, which is in agreement with the quantitative results from a singlevoxel H-1 MR spectroscopy study of Moats et a1 (15). If it is assumed that NAA is present only in neuronal bodies and axons (17), reduction of NAA concentration strongly suggests reduction of the volume ratio of neuronal to nonneuronal cells. Because neuronal loss (necrosis) or volume reduction (eg, loss of dendritic connections) in AD is often accompanied by reactive gliosis (6), this is the likely explanation for decreased NAA levels in AD patients.
It has been previously shown (18) that acute insults such as ischemia or inflammation can lead to reversible decreases in NAA levels, which appear to be due to transient neuronal metabolic disturbances. It is possible, therefore, that reductions in NAA levels in AD patients do not necessarily indicate neuronal loss but rf flea potentially reversible metabolic at normalities. AD is, however, a slowly prc gressive degenerative disease, and it is nc characterized by acute inflammation c ischemia. Hence, this possible explana tion for NAA level reductions in AD aF pears to be less likely.
Finally, it is possible that T1 or T changes were responsible for NAA signa intensity decreases. However, Chris tiansen et a1 (16) reported increased T values for NAA in the frontal lobe of AI patients. Increased T2 would tend to in crease signal intensity, especially at rela tively long echo times, This raises th possibility that increased T2 may hav offset the NAA signal intensity decrease! and the extent of neuronal loss ma therefore be underestimated by change in NAA level. Because of the cwsiderabl amount of additional time needed for th subjects to remain in the magnet, it wa not possible to perform relaxation tim measurements in the current study.
The current results showed no statisti cally significant changes in levels of cha line-or creatine-containing metabolite! The absence of changes in choline mea surements in AD patients differs fron findings suggestive of increased cholinl levels in AD patients in our previou studies (8,9), in which metabolite ratio were used, and in others' studies ( changes in choline levels in AD patients are due primarily to variations in T1 and T2. MR spectroscopic imaging in this study was performed at a shorter echo time (135 msec) than that used (272 msec) in our earlier studies (8,9). If the choline level increase observed previously in AD patients was due to a T2 prolongation of the choline resonance, then it is possible that this increase would remain undetected at examination with the shorter echo time used in this study. However, Huang et a1 (21) reported increased choline level in AD patients examined with an echo time as short as 30 msec. Furthermore, preliminary measurements of T1 and T2 revealed similar values in T2 for choline in AD patients and elderly individuals with normal cognition (15). Therefore, relaxation time differences do not appear to account totally for the discrepant findings of choline level changes in AD patients.
A second possibility is that regional variations in choline concentrations may account for the discrepancy. For example, Huang et a1 (21) found increased levels of choline only in the primary visual cortex of AD patients but not in the left and right parietal cortexes. Finally, heterogeneity of the patient population is another possibility that may account for the discrepancy. People with AD have different genotypes for apolipoprotein E, which pose different degrees of risk for development of AD. In addition, some isoform-specific interactions between apolipoprotein E and pathologic lesions have been demonstrated in patients with AD (22). This raises the possibility that, in cases of AD, differences in apolipoprotein E may account for differences in the metabolism of membrane phospholipids (23) that regulate the structure and stability of membranes. Such differences might thus be reflected as differences in concentrations of cholinecontaining membrane molecules, which are detected as an increase in choline level at H-1 MR spectroscopic imaging. Apolipoprotein E data were not available in the patients included in this study; therefore, such a subtype analysis could not be performed.
Our second major finding was that NAA reductions in frontal and posterior gray matter of AD patients cannot be explained in terms of structural variations measured at MR imaging. This analysis was made possible by using information from coregistered MR imaging segmentation data, which were reported earlier by Tanabe et a1 (3) . Our analysis also replicated previous MR spectroscopic imaging results from this laboratory by MacKay et a1 (10). However, the accuracy of image segmentation data was compromised in the study by MacKay et al, because MR images were not obtained from contiguous sections and did not cover the entire brain.
This result is important because it documents that changes in NAA levels in AD patients are not simply a reflection of differences in the tissue composition of M R spectroscopic imaging voxels. This result also suggests that changes in NAA levels provide information in addition to that acquired at MR imaging, which may be used to improve diagnostic classification. Furthermore, these results emphasize the value of MR imaging segmentation data for analysis and interpretation of H-1 MR spectroscopic imaging data, and we suggest that this approach may be used to improve analysis of data from other MR spectroscopic studies. For example, our analysis revealed that reductions in NAA levels in frontal white matter of AD patients were simply an artifact of increased hyperintense white matter in this region, which provided no information in addition to that already available from MR imaging.
The third finding was that changes in NAA levels in control subjects correlated with the amount of gray matter enclosed in the MR spectroscopic imaging voxels, which suggested the presence of higher NAA levels in gray matter than in white matter. This result is consistent with those of previous studies by Hetherington et a1 (24) in nonelderly control subjects and by Lim et a1 (25) of normal aging, both of whom used regression analysis to predict NAA concentrations in pure gray and pure white matter, with higher levels seen in gray matter than in white matter. Unlike in the control subjects in our study, we found no correlation between NAA levels and the amount of gray matter in AD patients, which indicated the presence of similar NAA levels in both gray and white matter, presumably because of reduced NAA levels in the gray matter of AD patients.
It is possible that the prominent reductions of NAA levels in AD patients' gray matter but not in white matter reflect the fact that cortical neurons are directly involved in the pathologic process of AD. The correlation of NAA level changes with voxel tissue composition also showed that NAA levels are decreased in regions with hyperintense white matter, which is consistent with previous reports (26) from this laboratory. As completely automated spectral fitting programs become more widely available, it will be 28 32 L Control AD a.
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possible to correlate the metabolite concentration with the measured tissue composition for each voxel on images of the brain. This approach would be expected to provide additional information and possibly to increase discriminative power for differentiation of various diseases. The fourth major finding was that NAA levels in parietal mesial cortex in AD patients showed a weak but statistically significant correlation with MMSE score. No correlation was found between MMSE score and NAA levels in frontal gray matter. This result is consistent with the concept that neuronal loss in the parietal lobe is chiefly responsible for the impairment of some cognitive functions in patients with AD. Others (20,21) have also reported a correlation of NAA levels with dementia severity. This result is encouraging because it supports the suggestion that NAA level reductions are associated with diminished brain function, presumably precipitated by means of neuronal loss or volume reduction (eg, loss of dendritic connections). In addition, this result emphasizes the possibility that sequential measurements of NAA levels may be a useful and objective means to document the progression of AD and the results of treatment. 
mmol/L.
Of the image segmentation variable only the percentage of sulcal CSF showe! a weak but statistically significant correld tion with severity of dementia. Perhap both NAA level and percentage of sulc, CSF, more than the other measures, closel reflect neuronal loss resulting in c o p tive impairment.
The fifth finding was that changes b NAA levels in mesial cortex did not in: prove the classification power relative t percentage of cortical gray matter locc This finding does not support the rnul: from our previous study (10) of the fror! toparietal brain, which suggested ths combinations of MR imaging and H-1 Yi spectroscopic imaging findings impror. classification power relative to the use t ' either measure alone. That previous stud was limited because of a small sample SUI (six AD patients, 11 control subjects), us of a relatively long echo time (272 msv. at spectroscopic imaging, and acquisitia of MR images with an intersection gz: that thereby excluded up to 30% of tS. brain. In the present study, we include. 4.3 times more patients and 1.5 timt more control subjects, acquired spec% scopic imaging data with a much short[ echo time (135 msec), and obtained V images contiguously across the enc brain. These differences-especially neity of AD-may explain the discrepancy between findings from this study and those from the earlier one.
There are several limitations to the present study. A first limitation is that H-1 MR spectroscopic imaging was performed in a frontoparietal region of the brain, which is not necessarily the region known to be most affected by AD. The greatest changes in AD are expected in the hippocampus and temporal lobe, as well as in regions of the surface cortex of the frontal and parietal lobes. These brain regions were not accessible with MR spectroscopic imaging at the time this study began. Subsequently, techniques have been developed to perform H-1 MR spectroscopic imaging of the hippocampus and mesial temporal lobe regions, in which striking NAA level reductions have been found in the hippocampal region of patients with epilepsy (27). Other results (28) from this laboratory have shown reduced NAA levels in the hippocampal region of AD patients. In addition, we documented that these NAA level reductions were to a large extent independent of hippocampal volume loss measured at MR imaging and contributed substantially to the discrimination of AD patients from control subjects, in contrast to the finding in the present study.
Furthermore, we (29) and others (30) have developed new multisection H-1 MI: spectroscopic imaging techniques that facilitate study of metabolic changes in large sections of the brain, including surface cortex. These techniques make use of outer-volume suppression pulses (30), lipid nulling (31), or data processing techniques (29) to reduce interference of the cortical metabolite signals with strong resonances from subcutaneous lipids. Recell tly, Tedeschi et al (32) performed multisvction H-l MR spectroscopic imaging in patients with AD and found marked chmges in NAA metabolite ratios in the associative cortexes, similar to the pattern of metabolic decrements reported in a number of PET studies (5).
A second limitation of this study was that the echo time we used was still too 1011,q for the measurement of myo-inositol. which has been shown to be elevated in cases of AD (33) and other conditions, inc!uding Creutzfeldt-Jakob disease (34) and frontotemporal dementia (20). Shonk et a1 (35) have further reported that the ratio of myo-inositol to NAA can be used to clearly discriminate patients with AD from healthy elderly individuals. Furthermore, Ernst et a1 (20) examined patients Wit11 AD and those with frontotemporal dementia and found. elevated myo-inosiVolume 207 Number 1 to1 levels in the temporoparietal cortex of AD patients, whereas these levels were elevated in the frontal cortex in patients with frontotemporal dementia; this result suggested the possibility that findings of myo-inositol level may be useful for differentiation of these two conditions.
Multisection H-1 MR spectroscopic imaging with an echo time of 20-30 msec, with which detection of regional changes of myo-inositol levels is possible, has been performed (36), but at the expense of greater lipid contamination of the metabolite resonances. In the future, techniques should be developed that use multisection or three-dimensional acquisition to depict regional changes in levels of NAA and other metabolites (including myo-inositol) in multiple brain regions. It is expected that the ability to sample many areas of the brain and observe a number of different metabolites, which change in dementia, wiU lead to improved discriminative power to identify AD.
Recently, other groups (25,31) have developed automated spectral analysis software to evaluate MR spectra from a large number of voxels, which eliminates the highly subjective approach of voxel selection from discrete regions. Although an automated spectral analysis program is under development at this laboratory, it was not available at the time of this study.
A potential source of bias in this study could be the difference in the distribution of sex and age between the groups. Despite an imbalance in the number of women and men in the groups, analysis of covariance demonstrated no group effect attributable to sex. The effect of sex on changes in NAA levels and amount of cortical gray matter loss can be inferred from the scatter plots in Figure 4 .
As far as age effects are concerned, Lim and Spielman (25) recently reported a trend of reduced NAA levels in the gray matter of healthy elderly when compared with the levels in nonelderly control subjects, which raises the possibility that NAA levels in gray matter may be reduced during normal aging. Therefore, agerelated changes in NAA levels may skew results between groups if the groups are not carefully matched in terms of age. In this study, there were no such age-related changes in either AD patients or control subjects. In addition, we tested whether differences in NAA !evels between the groups remained statistically significant after adjustment for the age difference and found no contribution from age.
Taken together, these results imply that the abnormal NAA levels in AD patients cannot be explained simply in terms of the different age. distribution of AD patients and control subjects in this study.
Finally, the contrast between gray and white matter is typically superior on heavily T1-weighted MR images compared with that on T2-weighted images, such as were acquired in this study. Misclassification of gray and white matter may have affected the calculation of percentage of gray matter and the tissue composition of the imaging voxels. However, at the time of this study, the segmentation software was limited to the processing of T2-weighted images only. Since then, we have developed software to process both Ti-and T2-weighted images (37) and have found no statistically significant differences between the two methods as regards the gray and white matter calculations.
Notwithstanding the limitations discussed above, our present results agree with previous observations of reduced levels of NAA in patients with AD, verify that these metabolite changes are independent of variations in the composition of MR spectroscopic imaging voxels, and show that changes in NAA levels correlate with severity of dementia. However, NAA measurements in the frontoparietal brain are of limited use for premorbid diagnosis of AD because of the overlap with such values in healthy elderly persons. Nevertheless, the additional information obtained with H-1 MR spectroscopic imaging may improve our understanding of the pathologic processes that underlie Alzheimer disease.
